LUNG CANCER

The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung cancer.

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options for a patient with metastatic non–small cell lung cancer (NSCLC), with participants.

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung cancer in the second article of a 2-part series.

Abenacianine, a tumor-targeted fluorescent imaging agent, received fast track designation from the FDA after demonstrating its safety and efficacy in visualizing lung tumors in a phase 2 study.

Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.

The phase 1 INSIGHT-003 trial of efti, pembrolizumab, and chemotherapy for first-line advanced nonsquamous NSCLC has completed enrollment.

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical trial results.

Recent regulatory activities suggest that the understanding of TROP2-directed therapies remains muddled.

Joseph Greer, PhD, discussed a study evaluating in-person vs telehealth modalities of early integrated palliative care for patients with advanced lung cancer.

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the MARIPOSA trial in patients with EGFR-mutated non–small cell lung cancer in the first article of a 2-part series.

The FDA granted priority review to taletrectinib in ROS1-positive advanced NSCLC, with a target decision date of June 2025.

Luis E. Raez, MD, discusses the current liquid biopsy options for patients with lung cancer through assessing circulating tumor DNA.

During a Case-Based Roundtable® event, Chul Kim, MD, moderated a discussion on current use of ALK TKIs in lung cancer in the second article of a 2-part series.

In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.

Lung cancer innovations are not only extending lives but also enhancing the quality of life for patients, offering renewed hope to millions worldwide.

With this approval, zenocutuzumab is the first FDA-approved therapy for patients with NRG1 fusion tumors.

The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.

The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its primary end point of overall survival.

Oleg Gligich, MD, discusses utilizing circulating tumor DNA to assess patients with lung cancer.

Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists for optimizing patient care in this rapidly changing field.

The TROPION-Lung12 trial uses a circulating tumor DNA assay to preoperatively screen patients with non–small cell lung cancer for eligibility in post-surgical adjuvant treatment regimens.

The phase 1 INSIGHT-003 trial showed that adding eftilagimod alpha to pembrolizumab and chemotherapy achieved a median overall survival of 32.9 months in metastatic non–small cell lung cancer.

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in patients with squamous non–small cell lung cancer.

Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, including prophylactic antibiotics, good skin hygiene, and insights from the phase 2 COCOON study, can help manage potential adverse effects and improve treatment outcomes.